BEIJING, July 21, 2014 /PRNewswire/ -- Sinovac Biotech
Ltd. (NASDAQ: SVA), a leading provider of biopharmaceutical
products in China, announced today
that it has been selected by the Beijing Health Bureau as the sole
supplier of inactivated hepatitis A vaccine in pre-filled syringe
dosage to the Expanded Program of Immunization (EPI) for
Beijing. The tender is valued at
approximately 16 million RMB. The
vaccines purchased by the Beijing Health Bureau will be used for
the period from 2014 to 2016. The Company expects to begin delivery
in the coming months upon the demand.
Mr. Weidong Yin, Chairman,
President and CEO of Sinovac, commented, "We are pleased to have
been selected again as the only supplier of the inactivated
hepatitis A vaccine in PFS presentation to the EPI in Beijing. With superior safety profile and
proven efficacy, Healive will continue to be administered to
newborns using our easy-to-use, pre-filled syringes. We look
forward to continuing to collaborate with government agencies to
control and prevent diseases with top-quality vaccines both in
China and around the world."
Healive is the first inactivated hepatitis A vaccine developed,
produced and marketed by a China-based manufacturer. Healive was launched
by Sinovac in 2002 and is currently available in adult and
pediatric dosages. The hepatitis A vaccine has been included in
China's national immunization
program since February 2008.
About Sinovac
Sinovac Biotech Ltd. is a China-based biopharmaceutical company that
focuses on the research, development, manufacturing, and
commercialization of vaccines that protect against human infectious
diseases including hepatitis A and B, seasonal influenza, H5N1
pandemic influenza (avian flu), H1N1 influenza (swine flu), and
mumps, as well as animal rabies vaccine for canines. The Company
filed a new drug application for enterovirus 71 (against hand, foot
and mouth disease) with China Food & Drug Administration. In
2009, Sinovac was the first company worldwide to receive approval
for its H1N1 influenza vaccine, Panflu.1, and has manufactured it
for the Chinese Central Government, pursuant to the
government-stockpiling program. The Company is also the only
supplier of the H5N1 pandemic influenza vaccine to the
government-stockpiling program. Sinovac is developing a number of
new pipeline vaccines including vaccines for pneumococcal
polysaccharides, pneumococcal conjugate, varicella, and sIPV.
Sinovac sells its vaccines mainly in China and exports selected vaccines to
Mongolia, Nepal, and the
Philippines. Sinovac has also been granted a license to
commercialize seasonal flu vaccine in Mexico and hepatitis A vaccine in Chile.
Contact
Sinovac Biotech Ltd.
Helen Yang / Chris Lee
Tel: +86-10-8279-9659 / 9696
Fax: +86-10-6296-6910
Email: ir@sinovac.com
ICR Inc.
Bill Zima
U.S: 1-646-308-1707
Email: william.zima@icrinc.com
SOURCE Sinovac Biotech Ltd.